Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Khartis is a drug discovery company developing oral therapies for immune-mediated and chronic diseases, with a focus on treatments and care.
CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.
Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments.
Sidewinder Therapeutics is a biotechnology company that offers life-saving therapies for cancer and rare diseases.
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
Vertero Therapeutics is using cutting-edge research outside of the brain to treat neurodegenerative illnesses.
KalVista Pharmaceuticals focuses on developing oral medicines, particularly for managing hereditary angioedema.
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
Be Biopharma develops engineered B cell medicines for serious genetic diseases.
XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.
TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3K malignancies.
Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.
Tome Biosciences is a biotechnology company that develops programmable gene insertion technology.
Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
Longwood Fund has invested in 56 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Longwood Fund's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Life Science. The firm invests across 17 different industry categories.
Among tracked funding rounds, Tome Biosciences received $213.0M in a Series A round. Longwood Fund's total known invested capital is $4.3B.
Longwood Fund's average investment size is $77.3M across its portfolio of 56 companies.
Recent Longwood Fund portfolio additions include Khartis Therapeutics, Coultreon Biopharma, Neomorph, Sidewinder Therapeutics, Evommune. These companies were founded in 2020 or later.